Your browser is no longer supported. Please, upgrade your browser.
BriaCell Therapeutics Corp.
Index- P/E- EPS (ttm)- Insider Own18.90% Shs Outstand14.33M Perf Week14.16%
Market Cap72.81M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.01M Perf Month-4.69%
Income- PEG- EPS next Q- Inst Own33.63% Short Float4.89% Perf Quarter37.67%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.06 Perf Half Y-7.64%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-70.97%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.81 - 9.00 Perf YTD21.82%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.56% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low80.47% ATR0.54
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)51.64 Volatility11.94% 12.29%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.31 Prev Close5.49
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume4.27M Price5.08
Recom- SMA202.46% SMA503.60% SMA20015.38% Volume1,327,171 Change-7.47%
Jul-14-21 07:22AM  
Jul-12-21 08:00AM  
Jul-08-21 11:20AM  
Jun-16-21 08:05AM  
Jun-10-21 08:05AM  
Jun-09-21 08:05AM  
Jun-07-21 07:50PM  
Jun-03-21 10:31AM  
Jun-02-21 07:12AM  
May-19-21 05:15PM  
May-11-21 06:30AM  
Apr-25-21 05:18AM  
Apr-21-21 08:00AM  
Apr-15-21 06:00PM  
Apr-12-21 01:45PM  
Mar-30-21 06:30AM  
Feb-26-21 02:24PM  
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.